Trending Stock News

$-0.13 EPS Expected for Cymabay Therapeutics, Inc. (CBAY); Kmg Chemicals (KMG) Sellers Decreased By 2.59% Their Shorts

Kmg Chemicals Incorporated (NYSE:KMG) had a decrease of 2.59% in short interest. KMG’s SI was 191,500 shares in February as released by FINRA. Its down 2.59% from 196,600 shares previously. With 119,400 avg volume, 2 days are for Kmg Chemicals Incorporated (NYSE:KMG)’s short sellers to cover KMG’s short positions. The SI to Kmg Chemicals Incorporated’s float is 2.5%. The stock increased 2.72% or $1.64 during the last trading session, reaching $61.86. About 138,384 shares traded. KMG Chemicals, Inc. (NYSE:KMG) has risen 169.63% since February 17, 2017 and is uptrending. It has outperformed by 152.93% the S&P500.

Analysts expect Cymabay Therapeutics, Inc. (NASDAQ:CBAY) to report $-0.13 EPS on March, 22.They anticipate $0.17 EPS change or 56.67% from last quarter’s $-0.3 EPS. After having $-0.21 EPS previously, Cymabay Therapeutics, Inc.’s analysts see -38.10% EPS growth. The stock increased 0.74% or $0.11 during the last trading session, reaching $14.98. About 1.40 million shares traded or 70.66% up from the average. Cymabay Therapeutics, Inc. (NASDAQ:CBAY) has risen 69.26% since February 17, 2017 and is uptrending. It has outperformed by 52.56% the S&P500.

Among 7 analysts covering Cymabay Therapeutics Inc (NASDAQ:CBAY), 7 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Cymabay Therapeutics Inc had 21 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Neutral” rating given on Wednesday, June 1 by H.C. Wainwright. The firm earned “Buy” rating on Tuesday, September 19 by Cantor Fitzgerald. Cantor Fitzgerald maintained the shares of CBAY in report on Wednesday, October 25 with “Buy” rating. The firm has “Buy” rating by Piper Jaffray given on Wednesday, January 31. On Wednesday, March 30 the stock rating was maintained by H.C. Wainwright with “Buy”. Leerink Swann maintained Cymabay Therapeutics, Inc. (NASDAQ:CBAY) rating on Tuesday, November 28. Leerink Swann has “Buy” rating and $16.0 target. Oppenheimer maintained Cymabay Therapeutics, Inc. (NASDAQ:CBAY) on Wednesday, January 10 with “Buy” rating. H.C. Wainwright upgraded the shares of CBAY in report on Monday, January 30 to “Buy” rating. As per Wednesday, January 4, the company rating was maintained by H.C. Wainwright. The firm earned “Buy” rating on Monday, September 11 by Piper Jaffray.

Cymabay Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to treat specialty and orphan diseases. The company has market cap of $830.59 million. It engages in developing seladelpar , a selective agonist of peroxisome proliferator-activated receptor delta, which has completed Phase 2 clinical study for the treatment of primary biliary cholangitis and homozygous familial hypercholesterolemia; and arhalofenate, which completed five Phase II clinical trials for the treatment of gout. It currently has negative earnings. The company's product candidate also includes MBX-2982, an oral G-protein coupled receptor agonist to treat type II diabetes.

Since August 14, 2017, it had 0 insider buys, and 30 sales for $34.79 million activity. HATCHER DAVID L also sold $433,320 worth of KMG Chemicals, Inc. (NYSE:KMG) shares.

Investors sentiment decreased to 0.95 in 2017 Q3. Its down 0.71, from 1.66 in 2017Q2. It is negative, as 14 investors sold KMG Chemicals, Inc. shares while 47 reduced holdings. 21 funds opened positions while 37 raised stakes. 8.47 million shares or 0.73% less from 8.53 million shares in 2017Q2 were reported. Cornerstone Cap Management Ltd Liability reported 0.02% in KMG Chemicals, Inc. (NYSE:KMG). Millennium Management Limited invested in 7,844 shares or 0% of the stock. Alliancebernstein Limited Partnership stated it has 0% in KMG Chemicals, Inc. (NYSE:KMG). Dimensional Fund Advisors Lp has 0.01% invested in KMG Chemicals, Inc. (NYSE:KMG). Moreover, Schwab Charles Mgmt has 0% invested in KMG Chemicals, Inc. (NYSE:KMG) for 35,571 shares. California State Teachers Retirement System holds 0% or 14,669 shares in its portfolio. State Street reported 0% in KMG Chemicals, Inc. (NYSE:KMG). Bowling Mngmt Ltd Com invested in 0.22% or 26,393 shares. California-based Menta Ltd Liability Co has invested 0.04% in KMG Chemicals, Inc. (NYSE:KMG). Victory Mngmt has invested 0% of its portfolio in KMG Chemicals, Inc. (NYSE:KMG). Morgan Dempsey Cap Mngmt Limited Liability Company, Wisconsin-based fund reported 37,762 shares. Cadence Capital Management Lc reported 32,319 shares. Indexiq Advsr Ltd has invested 0.04% in KMG Chemicals, Inc. (NYSE:KMG). Los Angeles & Equity Research Inc holds 17,035 shares. Ameritas Investment Ptnrs has invested 0% in KMG Chemicals, Inc. (NYSE:KMG).

Among 5 analysts covering KMG Chemicals (NYSE:KMG), 3 have Buy rating, 0 Sell and 2 Hold. Therefore 60% are positive. KMG Chemicals had 9 analyst reports since August 12, 2015 according to SRatingsIntel. The firm earned “Neutral” rating on Wednesday, August 26 by Global Hunter Securities. The stock of KMG Chemicals, Inc. (NYSE:KMG) has “Hold” rating given on Monday, August 31 by Zacks. KeyBanc Capital Markets maintained KMG Chemicals, Inc. (NYSE:KMG) rating on Wednesday, December 13. KeyBanc Capital Markets has “Buy” rating and $70.0 target. The stock of KMG Chemicals, Inc. (NYSE:KMG) has “Strong-Buy” rating given on Wednesday, August 12 by Zacks. As per Wednesday, December 14, the company rating was downgraded by Gabelli. The rating was upgraded by Gabelli on Monday, May 1 to “Buy”. Seaport Global Securities upgraded KMG Chemicals, Inc. (NYSE:KMG) rating on Friday, December 11. Seaport Global Securities has “Buy” rating and $26 target.

Leave a Reply

Your email address will not be published. Required fields are marked *